C07K 16/2821
Against icam molecules
Official title: {against ICAM molecules, e.g. CD50, CD54, CD102}
C07K16/2821 (Against icam molecules) appears on 193 US grants and 238 published applications in this corpus.
Search patents in C07K- Granted patents
- 193
- Published applications
- 238
- Assignees
- 101
- Inventors
- 287
- Latest grant
- 24 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 4 | 0 |
| 1995 | 3 | 0 |
| 1996 | 5 | 0 |
| 1997 | 13 | 0 |
| 1998 | 13 | 0 |
| 1999 | 8 | 0 |
| 2000 | 8 | 0 |
| 2001 | 2 | 2 |
| 2002 | 1 | 8 |
| 2003 | 5 | 9 |
| 2004 | 4 | 6 |
| 2005 | 4 | 8 |
| 2006 | 0 | 3 |
| 2007 | 1 | 2 |
| 2008 | 6 | 6 |
| 2009 | 3 | 12 |
| 2010 | 4 | 5 |
| 2011 | 3 | 4 |
| 2012 | 0 | 9 |
| 2013 | 5 | 10 |
| 2014 | 6 | 9 |
| 2015 | 3 | 5 |
| 2016 | 4 | 8 |
| 2017 | 4 | 5 |
| 2018 | 2 | 4 |
| 2019 | 1 | 9 |
| 2020 | 29 | 45 |
| 2021 | 34 | 28 |
| 2022 | 6 | 6 |
| 2023 | 5 | 18 |
| 2024 | 4 | 9 |
| 2025 | 1 | 3 |
| 2026 | 1 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- CD38 and ICAM1 antibodies and uses thereof24 Mar 2026US 12,583,932 B2The Regents of the University of California
- Antibody specifically binding to ICAM-1 and use thereof8 Apr 2025US 12,269,884 B2Kumho Ht, Inc.
- Methods of treatment by targeting VCAM1 and MAEA24 Dec 2024US 12,173,073 B2Albert Einstein College of Medicine
- Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers9 Apr 2024US 11,951,132 B2Immatics Biotechnologies GmbH
- Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers5 Mar 2024US 11,918,607 B2Immatics Biotechnologies GmbH
- Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer17 Sep 2026US 2026/0273055 A1Cornell University
- Multispecific molecules for modulating t-cell activity, and uses thereof27 Aug 2026US 2026/0248911 A1Regeneron Pharmaceuticals, Inc.
- Monobodies binding to intercellular adhesion molecule 2 (icam-2)27 Aug 2026US 2026/0250391 A1
- Fibrosis treatment containing icam-1 inhibitor30 Jul 2026US 2026/0217832 A1Fnctbiotech Inc.
- Fc-Engineered Monoclonal Antibodies Refractory to Tumor Immunosuppressive ICAM-1/CD549 Apr 2026US 2026/0098858 A1Navrogen, Inc.
Most cited
By later US patents
- Simultaneous stimulation and concentration of cells422US 6,797,514 B2XCYTE Therapies, Inc. · 2004
- Simultaneous stimulation and concentration of cells398US 6,867,041 B2XCYTE Therapies, Inc. · 2005
- Simultaneous stimulation and concentration of cells383US 6,905,874 B2XCYTE Therapies, Inc. · 2005
- Recombinant antibodies for human therapy283US 5,658,570 AIDEC Pharmaceuticals Corporation · 1997
- Recombinant antibodies for human therapy169US 5,750,105 AIDEC Pharmaceuticals Corporation · 1998